This is an old revision of this page, as edited by Citation bot(talk | contribs) at 07:58, 2 October 2022(Alter: template type. Add: s2cid, pmid, pages, issue, volume, doi, journal, authors 1-18. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Whoop whoop pull up | #UCB_webform 1281/2176). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 07:58, 2 October 2022 by Citation bot(talk | contribs)(Alter: template type. Add: s2cid, pmid, pages, issue, volume, doi, journal, authors 1-18. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Whoop whoop pull up | #UCB_webform 1281/2176)
Arbaclofen placarbil (/ɑːrˈbækloʊfɛnpləˈkɑːrbɪl/ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.[1]
It is being developed as an addiction medicine to treat alcoholism. [2] It is also studied as a potential therapeutic for some autistic subjects.[3]